Actively Recruiting
Evaluating Cemsidomide Plus Dexamethasone for RelapsedRefractory Multiple Myeloma in a Phase 2 Open-Label Study
Led by C4 Therapeutics, Inc. · Updated on 2026-10-30
100
Participants Needed
60
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of cemsidomide combined with dexamethasone in people with relapsed or refractory multiple myeloma, a type of blood cancer. This Phase 2, open-label, single-arm, multicenter study aims to understand the treatments ability to fight the disease as well as its safety, how it is processed in the body, and how it affects the body over time. Participants will take cemsidomide orally once daily for 14 days followed by 14 days off in each 28-day treatment cycle, along with dexamethasone taken orally once a week on days 1, 8, 15, and 22 of each cycle. Treatment continues until certain stopping criteria are met. This study involves only one treatment group receiving this combination. Throughout the study, participants will be monitored regularly for response to treatment, including overall response rate, duration and time to response, progression-free survival, and overall survival, with assessments lasting up to around 43 months. Safety is closely tracked by recording any adverse events during and shortly after treatment. Blood samples will be collected to measure cemsidomide levels during the first four months. Participants remain in the study for ongoing evaluation until study completion.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Research Team
S
Study Medical Officer
P
Patient Navigator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here